JP2017518303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518303A5 JP2017518303A5 JP2016570806A JP2016570806A JP2017518303A5 JP 2017518303 A5 JP2017518303 A5 JP 2017518303A5 JP 2016570806 A JP2016570806 A JP 2016570806A JP 2016570806 A JP2016570806 A JP 2016570806A JP 2017518303 A5 JP2017518303 A5 JP 2017518303A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- amino acid
- polypeptide
- seq
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 104
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 104
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 104
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 83
- 108060003951 Immunoglobulin Proteins 0.000 claims description 15
- 102000018358 immunoglobulin Human genes 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 7
- 239000000710 homodimer Substances 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 description 42
- 102000016970 Follistatin Human genes 0.000 description 37
- 108010014612 Follistatin Proteins 0.000 description 37
- 210000003205 muscle Anatomy 0.000 description 35
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 208000021642 Muscular disease Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 4
- 108010023082 activin A Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 101000931668 Homo sapiens Follistatin Proteins 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 102000050536 human FST Human genes 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462007908P | 2014-06-04 | 2014-06-04 | |
| US62/007,908 | 2014-06-04 | ||
| PCT/US2015/034245 WO2015187977A1 (en) | 2014-06-04 | 2015-06-04 | Methods and compositions for treatment of disorders with follistatin polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142333A Division JP6856716B2 (ja) | 2014-06-04 | 2019-08-01 | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518303A JP2017518303A (ja) | 2017-07-06 |
| JP2017518303A5 true JP2017518303A5 (enExample) | 2018-02-08 |
| JP6568110B2 JP6568110B2 (ja) | 2019-08-28 |
Family
ID=54767384
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570806A Expired - Fee Related JP6568110B2 (ja) | 2014-06-04 | 2015-06-04 | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
| JP2019142333A Expired - Fee Related JP6856716B2 (ja) | 2014-06-04 | 2019-08-01 | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
| JP2021044545A Pending JP2021095416A (ja) | 2014-06-04 | 2021-03-18 | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142333A Expired - Fee Related JP6856716B2 (ja) | 2014-06-04 | 2019-08-01 | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
| JP2021044545A Pending JP2021095416A (ja) | 2014-06-04 | 2021-03-18 | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10023621B2 (enExample) |
| EP (2) | EP3152237B1 (enExample) |
| JP (3) | JP6568110B2 (enExample) |
| KR (4) | KR102132144B1 (enExample) |
| CN (2) | CN106795224B (enExample) |
| AU (2) | AU2015269333B2 (enExample) |
| BR (1) | BR112016028520A2 (enExample) |
| CA (1) | CA2950754C (enExample) |
| EA (2) | EA202090632A1 (enExample) |
| MA (2) | MA51074A (enExample) |
| MX (2) | MX382908B (enExample) |
| WO (1) | WO2015187977A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| EP2315602A4 (en) | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
| CA2898121A1 (en) | 2013-01-25 | 2014-07-31 | Shire Human Genetic Therapies, Inc. | Follistatin in treating duchenne muscular dystrophy |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| JP6568110B2 (ja) | 2014-06-04 | 2019-08-28 | アクセルロン ファーマ， インコーポレイテッド | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| CA2980757A1 (en) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| BR112018067747A2 (pt) * | 2016-03-04 | 2019-01-08 | Shire Human Genetic Therapies | proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne |
| US10905766B2 (en) | 2017-03-23 | 2021-02-02 | Oregon State University | Therapeutic compositions and methods for treatment of muscle wasting diseases |
| KR101822633B1 (ko) * | 2017-08-22 | 2018-01-26 | (주)진셀팜 | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 |
| WO2019046903A1 (en) * | 2017-09-08 | 2019-03-14 | Baker Heart and Diabetes Institute | THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT |
| CN108218985B (zh) * | 2017-12-12 | 2021-04-30 | 山西农业大学 | 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用 |
| CA3093716A1 (en) * | 2018-03-16 | 2019-09-19 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
| US11672845B2 (en) * | 2018-03-21 | 2023-06-13 | Soulyoung Biotech Co., Ltd. | Composition for promoting local muscle growth or slowing down or preventing local muscle atrophy and use thereof |
| WO2019191204A1 (en) * | 2018-03-28 | 2019-10-03 | Acceleron Pharma Inc. | Follistatin polypeptides for the treatment of muscle contracture |
| AU2019269702A1 (en) * | 2018-05-17 | 2020-12-24 | Housey Pharmaceutical Research Laboratories, L.L.C. | Inhibition of follistatin |
| US12246042B2 (en) | 2018-08-29 | 2025-03-11 | Myos Corp. | Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| AU2022214780A1 (en) * | 2021-01-26 | 2023-09-07 | Immunis, Inc. | Molecular superstructure and methods of use thereof |
| KR20250024825A (ko) | 2022-06-15 | 2025-02-19 | 유씨비 바이오파마 에스알엘 | 폴리스타틴-fc 융합 단백질 |
| CA3259309A1 (en) | 2022-06-15 | 2023-12-21 | UCB Biopharma SRL | Fusion protein for the prevention, treatment or improvement of kidney disease |
| EP4630443A1 (en) * | 2022-12-07 | 2025-10-15 | Kamino ApS | Extracellular matrix binding compounds for the localized loading of therapeutic or diagnostic agents |
| KR102971166B1 (ko) * | 2022-12-09 | 2026-06-01 | (주)케어젠 | 연골 재생용 펩타이드 및 이의 용도 |
| TW202530250A (zh) * | 2024-01-25 | 2025-08-01 | 大陸商四川至善唯新生物科技有限公司 | 編碼卵泡抑素的核酸及其用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5041538A (en) | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| US5182375A (en) | 1987-08-28 | 1993-01-26 | The Salk Institute For Biological Studies | DNA encoding follistatin |
| DE69233480T2 (de) | 1991-02-08 | 2006-01-05 | Progenics Pharmaceuticals, Inc. | CD4-gamma2- und CD4-IgG2-Chimären |
| EP0661993B1 (en) | 1992-09-16 | 1997-05-07 | Genentech, Inc. | Protection against liver damage by hgf |
| DE69434934D1 (de) | 1993-10-14 | 2007-04-12 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
| US6686198B1 (en) | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| GB2306481A (en) | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| WO1999006559A1 (en) | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| JP2003517580A (ja) | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
| CA2365449A1 (en) | 1999-04-19 | 2000-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Inhibitor of the growth of androgen-independent tumor |
| WO2001009368A1 (en) | 1999-07-30 | 2001-02-08 | The General Hospital Corporation | Follistatin antagonists |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| BR0307907A2 (pt) | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
| CN1993048A (zh) * | 2002-02-21 | 2007-07-04 | 惠氏公司 | 包含促滤泡素抑制素结构域的蛋白质 |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| WO2004082710A1 (en) | 2003-03-21 | 2004-09-30 | Lorantis Limited | Treatment of allergic diseases using a modulator of the notch signaling pathway |
| WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| WO2005025601A1 (en) | 2003-09-15 | 2005-03-24 | Monash University | Follistatin isoforms and uses thereof |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| WO2005032578A1 (en) | 2003-10-06 | 2005-04-14 | Monash University | Therapeutic method |
| JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| JP2008507288A (ja) * | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| MX2007000976A (es) | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| US7888486B2 (en) | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| US20070149458A1 (en) * | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| WO2008067480A2 (en) | 2006-11-29 | 2008-06-05 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| CA2672758C (en) | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2315602A4 (en) * | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
| KR20110031951A (ko) * | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| EP3202459B1 (en) * | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| KR101603001B1 (ko) * | 2010-08-25 | 2016-03-11 | 에프. 호프만-라 로슈 아게 | Il-18r1에 대한 항체 및 그의 용도 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| ES2663993T3 (es) | 2012-05-17 | 2018-04-17 | Paranta Biosciences Limited | Uso de folistatina o de un inhibidor de activina para prevenir o tratar la disfunción del injerto de tejido |
| EP2866826B1 (en) * | 2012-06-27 | 2025-08-06 | Meiragtx UK II Limited | Combination for treating an inflammatory disorder |
| CA2898121A1 (en) * | 2013-01-25 | 2014-07-31 | Shire Human Genetic Therapies, Inc. | Follistatin in treating duchenne muscular dystrophy |
| WO2014187807A1 (en) * | 2013-05-21 | 2014-11-27 | Arcarios B.V. | Follistatin derivatives |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| JP6568110B2 (ja) | 2014-06-04 | 2019-08-28 | アクセルロン ファーマ， インコーポレイテッド | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
| CA2980757A1 (en) | 2015-03-26 | 2016-09-29 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| AU2018266893A1 (en) | 2017-05-12 | 2019-12-05 | Takeda Pharmaceutical Company Limited | Recombinant follistatin-Fc fusion proteins and use in treating Duchenne muscular dystrophy |
-
2015
- 2015-06-04 JP JP2016570806A patent/JP6568110B2/ja not_active Expired - Fee Related
- 2015-06-04 CA CA2950754A patent/CA2950754C/en active Active
- 2015-06-04 MA MA051074A patent/MA51074A/fr unknown
- 2015-06-04 KR KR1020207003791A patent/KR102132144B1/ko not_active Expired - Fee Related
- 2015-06-04 KR KR1020207018965A patent/KR102305109B1/ko not_active Expired - Fee Related
- 2015-06-04 CN CN201580041740.2A patent/CN106795224B/zh not_active Expired - Fee Related
- 2015-06-04 EP EP15802909.0A patent/EP3152237B1/en active Active
- 2015-06-04 EA EA202090632A patent/EA202090632A1/ru unknown
- 2015-06-04 MA MA051075A patent/MA51075A/fr unknown
- 2015-06-04 MX MX2016015868A patent/MX382908B/es unknown
- 2015-06-04 WO PCT/US2015/034245 patent/WO2015187977A1/en not_active Ceased
- 2015-06-04 CN CN202110533308.2A patent/CN113583104A/zh active Pending
- 2015-06-04 BR BR112016028520A patent/BR112016028520A2/pt not_active Application Discontinuation
- 2015-06-04 EP EP20160287.7A patent/EP3721892B1/en active Active
- 2015-06-04 AU AU2015269333A patent/AU2015269333B2/en not_active Ceased
- 2015-06-04 KR KR1020177000297A patent/KR102077286B1/ko not_active Expired - Fee Related
- 2015-06-04 EA EA201692529A patent/EA035455B1/ru not_active IP Right Cessation
- 2015-06-04 US US14/731,009 patent/US10023621B2/en active Active
- 2015-06-04 KR KR1020217029755A patent/KR20210119546A/ko not_active Ceased
-
2016
- 2016-12-01 MX MX2021006017A patent/MX2021006017A/es unknown
-
2018
- 2018-06-12 US US16/006,025 patent/US10954279B2/en active Active
-
2019
- 2019-08-01 JP JP2019142333A patent/JP6856716B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-03 AU AU2020210315A patent/AU2020210315A1/en not_active Abandoned
-
2021
- 2021-03-18 JP JP2021044545A patent/JP2021095416A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7685737B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| ES2905912T3 (es) | Dominios variables de inmunoglobulina de unión a albúmina sérica mejorados | |
| JP7159148B2 (ja) | Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 | |
| EP4005585A1 (en) | Compositions and methods for treating right ventricular hypertrophy | |
| JP2019532996A5 (enExample) | ||
| AU2018201273A1 (en) | Fibronectin based scaffold domain proteins that bind to myostatin | |
| KR20200109330A (ko) | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 | |
| JP2019507589A5 (enExample) | ||
| JP7846169B2 (ja) | 細胞透過性ペプチド | |
| JP2010518079A5 (enExample) | ||
| JP2022552371A5 (enExample) | ||
| JP2011530599A5 (enExample) | ||
| JP2015522576A5 (enExample) | ||
| JP2017518303A (ja) | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 | |
| JP2017531613A5 (enExample) | ||
| JP2022514778A (ja) | 筋膜損傷の予防および治療におけるアネキシンの使用 | |
| FI3065763T4 (fi) | Il-22-dimeerin käyttö lääkkeen valmistamisessa suonensisäistä antoa varten | |
| JP2016536369A5 (enExample) | ||
| JP2020511494A5 (enExample) | ||
| JP2024526938A5 (enExample) | ||
| WO2018232353A4 (en) | Bacterial vaccine | |
| JP2020504081A5 (enExample) | ||
| JP2022169771A (ja) | タンパク質の半減期を増加させる方法 | |
| WO2019191204A1 (en) | Follistatin polypeptides for the treatment of muscle contracture | |
| MX2022002293A (es) | Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso. |